# A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol and Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

> **NCT01817764** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 707 (actual)

## Conditions studied

- Pulmonary Disease, Chronic Obstructive

## Interventions

- **DRUG:** Umeclidinium/vilanterol
- **DRUG:** Fluticasone propionate/salmeterol
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01817764
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-03-01
- **Primary completion:** 2013-10-01
- **Final completion:** 2013-10-25
- **Target enrollment:** 707 (ACTUAL)
- **Last updated:** 2017-11-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01817764

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01817764, "A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol and Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01817764. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*